Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 4,582.1	$ 3,666.4
Short-term investments	1,456.5	785.4
Accounts receivable, net of allowances of $40.3 (2016) and $44.3 (2015)	4,029.4	3,513.0
Other receivables	736.9	558.6
Inventories	3,561.9	3,445.8
Prepaid expenses and other	734.6	604.4
Total current assets	15,101.4	12,573.6
Other Assets
Investments	5,207.5	3,646.6
Goodwill	3,972.7	4,039.9
Other intangibles, net	4,357.9	5,034.8
Sundry	1,913.8	2,220.5
Total other assets	15,451.9	14,941.8
Property and equipment, net	8,252.6	8,053.5
Total assets	38,805.9	35,568.9
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,937.4	6.1
Accounts payable	1,349.3	1,338.2
Employee compensation	896.9	967.0
Sales rebates and discounts	3,914.9	2,560.1
Dividends payable	548.1	539.0
Income taxes payable	119.1	358.9
Other current liabilities	2,220.9	2,460.3
Total current liabilities	10,986.6	8,229.6
Other Liabilities
Long-term debt	8,367.8	7,972.4
Accrued retirement benefits	2,453.9	2,160.3
Long-term income taxes payable	688.9	868.9
Other noncurrent liabilities	2,228.2	1,747.4
Total other liabilities	13,738.8	12,749.0
Eli Lilly and Company Shareholders' Equity
Common stock-no par value Authorized shares: 3,200,000 Issued shares: 1,101,586 (2016) and 1,106,063 (2015)	688.5	691.3
Additional paid-in capital	5,640.6	5,552.1
Retained earnings	16,046.3	16,011.8
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss	(5,274.0)	(4,580.7)
Cost of common stock in treasury	(80.5)	(90.0)
Total Eli Lilly and Company shareholders' equity	14,007.7	14,571.3
Noncontrolling interests	72.8	19.0
Total equity	14,080.5	14,590.3
Total liabilities and equity	$ 38,805.9	$ 35,568.9